期刊文献+

食管鳞癌中多基因表达的层次聚类分析 被引量:2

暂未订购
导出
摘要 目的探讨ERCC1、TYMS、TUBB3、RRM1和TOP2A的基因表达模式与食管鳞癌临床病理特征的内在联系。方法收集29例未经系统性治疗的食管鳞癌患者的手术组织标本,通过液相芯片技术进行ERCC1、TYMS、TUBB3、RRM1和TOP2A的mRNA表达检测,并收集患者的临床病理信息。结果 29个标本中,24.14%(7/29)的标本显示出TYMS与TOP2A高表达,而TUBB3与RRM1的高表达率为6.90%(2/29)。单因素分析显示,ERCC1表达与肿瘤侵袭深度呈正相关(r s=0.469 2,P=0.010 2),与淋巴转移程度呈负相关(r s=-0.392 0,P=0.035 7)。TYMS表达与肿瘤侵袭深度呈负相关(r s=-0.471 8,P=0.009 8),与肿瘤临床分期呈负相关(r s=-0.430 5,P=0.019 7)。TUBB3表达与肿瘤淋巴转移程度呈负相关(r s=-0.420 5,P=0.023 1)。多基因层次聚类分析显示,ERCC1+TUBB3表达上调、TYMS+RRM1+TOP2A表达下调者的肿瘤侵袭深度与ERCC1+TUBB3表达下调、TYMS+RRM1+TOP2A表达上调者差异有统计学意义。结论 ERCC1、TYMS、TUBB3、RRM1和TOP2A是影响食管鳞癌临床病理特征的部分关键基因。
出处 《广东医学》 CAS CSCD 北大核心 2013年第21期3305-3307,共3页 Guangdong Medical Journal
  • 相关文献

参考文献15

  • 1SIEGEL R,NAISHADHAM D,JEMAL A. Cancer statistics,2012[J].CA:A Cancer Journal for Clinicians,2012,(01):10-29.
  • 2LIGHTDALE C J. Esophageal cancer.American College of Gastroenterology[J].American Journal of Gastroenterology,1999,(01):20-29.
  • 3OLAUSSEN K A,DUNANT A,FOURET P. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J].New England Journal of Medicine,2006,(10):983-991.
  • 4MARTINEZ BALIBREA E,ABAD A,MART(I)NEZ CARD(U)S A. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy[J].British Journal of Cancer,2010,(04):581-589.
  • 5LEVALLET G,BERGOT E,ANTOINE M. High TUBB3 expression,an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy,is regulated by K-Ras signaling pathway[J].Molecular Cancer Therapeutics,2012,(05):1203-1213.
  • 6ZHENG Z,CHEN T,LI X. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer[J].New England Journal of Medicine,2007,(08):800-808.
  • 7ARRIOLA E,MARCHIO C,TAN D S. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines[J].Laboratory Investigation,2008,(05):491-503.
  • 8HANAHAN D,WEINBERG R A. Hallmarks of cancer:the next generation[J].Cell,2011,(05):646-674.
  • 9ZHANG J,CUI Y,KUANG G. Association of the thymidylate synthase polymorphisms with esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma[J].Carcinogenesis,2004,(12):2479-2485.doi:10.1093/carcin/bgh247.
  • 10SCHNEIDER S,UCHIDA K,BRABENDER J. Downregulation of TS,DPD,ERCC1,GST-Pi,EGFR,and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer[J].Journal of the American College of Surgeons,2005,(03):336-344.

二级参考文献18

  • 1卢红,樊青霞,王瑞林,王留兴,赵培荣.耐紫杉醇食管鳞癌细胞株Ec9706/P-1的建立及特征[J].中国肿瘤临床,2007,34(13):731-734. 被引量:6
  • 2Millar J, Scullin P, Morrison A, et al. Phase Ⅱ study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer, 2005, 93:1112-1116.
  • 3Kroep JR, Pinedo HM, Giaccone G, et al. Phase Ⅱ study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Ann Oncol, 2004, 15:230-235.
  • 4Lorenzen S, Duyster J, Lersch C, et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer : final results of a phase Ⅱ trial. Br J Cancer, 2005, 92 : 2129-2133.
  • 5Assersohn L, Brown G, Cunningham D, et al. Phase Ⅱ study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol, 2004, 15:64-69.
  • 6Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small- cell lung cancer. J C lin Oucol, 2006, 24:4731-4737.
  • 7徐兵河.耐药问题和对策//孙燕,石远凯.临床肿瘤内科手册.第5版.北京:人民卫生出版社,2007:194-195.
  • 8Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 1999, 286: 487- 491.
  • 9Evans WE, McLeod HL. Pharmacogenomics -- drug disposition, drug targets, and side effects. N Engl J Med, 2003, 348:538- 549.
  • 10Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res, 2004, 64:3761-3766.

共引文献2

同被引文献18

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部